ARG1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, designed for loss-of-function studies of arginase 1 (ARG1). This product provides a heterogeneous pool of edited cells with targeted disruption of the ARG1 gene, enabling investigation of arginine metabolism in a human cervical adenocarcinoma background.
The parental HeLa cell line is a widely used model of cervical adenocarcinoma, originally derived from a patient with cervical cancer and characterized by HPV18 integration leading to p53 and retinoblastoma protein (RB) inactivation. These immortalized epithelial cells are a well-established platform for cancer biology research, including studies of oncogenic signaling, viral carcinogenesis, and metabolic reprogramming.
ARG1 encodes arginase 1, a manganese-dependent homotrimeric enzyme that catalyzes the hydrolysis of L-arginine to L-ornithine and urea, thereby depleting arginine availability. Its expression is regulated by cytokines such as IL-4, IL-10, and TGF-??, and by transcription factors including STAT3, STAT6, C/EBP??, and glucocorticoid receptor signaling. Downstream, ARG1 activity channels arginine toward ornithine, which serves as a precursor for polyamine synthesis (spermine and spermidine) via ornithine decarboxylase (ODC1) and for proline production. This metabolic shunt limits arginine supply for nitric oxide synthase (NOS2, NOS3), reducing nitric oxide production. ARG1 also interacts with urea cycle enzymes ASS1 and ASL, and its activity is pharmacologically inhibited by nor-NOHA. In immune contexts, ARG1-mediated arginine deprivation suppresses T-cell proliferation and effector functions by restricting arginine availability for protein translation and nitric oxide synthesis.
In HeLa cells, loss of ARG1 disrupts arginine metabolism, potentially altering polyamine biosynthesis, urea cycle intermediate flux, and nitric oxide production. Given the role of arginine in supporting rapid proliferation, ARG1 knockout in this cervical cancer model provides a system to examine how arginine depletion influences tumor cell growth, migration, and survival under nutrient stress. Moreover, because HeLa cells are often used in co-culture with immune cells, these polyclonal knockout cells facilitate studies of tumor-immune interactions, particularly the role of arginine availability in T-cell responses. This model is valuable for exploring the intersection of metabolic pathways and immune evasion strategies in cervical cancer.
These polyclonal knockout cells are suitable for a range of experimental applications, including investigation of arginine metabolism, urea cycle enzyme function in non-hepatic cells, and drug screening for arginase inhibitors. Representative assays include Western blotting for ARG1, arginase activity measurements, RT-qPCR, metabolomics profiling of arginine and ornithine, T-cell proliferation co-culture assays, immunofluorescence, RNA-seq, and migration/invasion assays. They also enable studies on cell viability under arginine deprivation. For additional information or technical support, please contact Ascent Research.
